INT199559

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2006
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 4.23
Pain Relevance 0.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Erbb2) plasma membrane (Erbb2) nucleus (Erbb2)
kinase activity (Erbb2) cytoplasm (Erbb2)
Anatomy Link Frequency
mesenchymal cell 1
Erbb2 (Mus musculus)
Pain Link Frequency Relevance Heat
fibrosis 101 96.40 Very High Very High Very High
Cannabinoid 57 74.24 Quite High
imagery 10 73.28 Quite High
Kinase C 1 26.92 Quite Low
Pain 4 6.16 Low Low
Inflammation 17 5.68 Low Low
agonist 15 5.00 Very Low Very Low Very Low
cytokine 14 5.00 Very Low Very Low Very Low
Cannabinoid receptor 7 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Recurrence 59 99.48 Very High Very High Very High
Bronchiolitis Obliterans 1 98.04 Very High Very High Very High
Pulmonary Fibrosis 68 96.60 Very High Very High Very High
Cancer 157 95.36 Very High Very High Very High
Breast Cancer 115 94.28 High High
Fibrosis 58 94.12 High High
Colon Cancer 6 92.60 High High
Disease 58 90.96 High High
Death 13 89.08 High High
Keloid Scars 2 85.80 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Both experimental and clinical evidence have indicated that the HER2 pathway interacts with the ER pathway with retrospective clinical studies suggesting an inverse relationship between ER and HER-2 expression.
HER2 Binding (interacts) of
1) Confidence 0.36 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2383915 Disease Relevance 0.59 Pain Relevance 0
Although no specific ligand for ErbB2 has been identified yet, this receptor is the preferred heterodimerization partner of the family [2].
ErbB2 Neg (no) Binding (ligand) of
2) Confidence 0.23 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2917429 Disease Relevance 0.45 Pain Relevance 0.04
However, this finding according to progesterone receptor status has not been confirmed either in a similar trial comparing letrozole with tamoxifen12 or by the Trans-ATAC investigators who investigated a subset of patients from whom tissue was able to assess a link between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC.13
HER2 Binding (link) of associated with recurrence
3) Confidence 0.20 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2690973 Disease Relevance 0.68 Pain Relevance 0
Some anticancer therapies, such as those targeting erbB2 (an EGF receptor family member) with monoclonal antibodies, might be considered for lung fibrosis therapy to reduce mesenchymal cell survival and resolve a fibrotic reaction.
erbB2 Spec (might) Binding (targeting) of in mesenchymal cell associated with fibrosis and pulmonary fibrosis
4) Confidence 0.19 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2940818 Disease Relevance 1.16 Pain Relevance 0.29
For example, cetuximab and trastuzumab bind to the EGFR and HER-2/neu receptor TKs respectively; these molecules are often overexpressed in colorectal (EGFR) and breast (HER-2/neu) cancers and the efficacy of cetuximab in the treatment of metastatic colorectal cancer (Cunningham et al 2004) and trastuzumab in the treatment of breast cancer (Slamon et al 2001; Piccart-Gebhart et al 2005; Romond et al 2005) has been demonstrated clearly.
HER-2 Binding (bind) of associated with cancer, breast cancer and colon cancer
5) Confidence 0.10 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.78 Pain Relevance 0
We examined the conventional clinicopathologic factors including the six different biological factors (ER, PR, p53, c-erbB2, bcl-2, and Ki-67) by immunohistochemistry and evaluated their association with clinical outcomes.
c-erbB2 Spec (examined) Binding (association) of
6) Confidence 0.06 Published 2007 Journal BMC Cancer Section Body Doc Link PMC2217558 Disease Relevance 0.56 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox